Sahlgrenska Science Park annually presents the Arvid Carlsson Award to an actor who, through innovation and science, contributes to the development of future health. This year’s recipient, Verigraft, has developed a regenerative medicine platform that makes it possible to convert donated tissue into personalized transplants. The technology eliminates the risk of rejection and reduces the need for lifelong immunosuppression – factors that can improve recovery and quality of life for patients with serious medical conditions.

The technology has already been evaluated in initial clinical studies and is now being further developed for application in cardiovascular diseases. Verigraft’s work represents the type of translational development – ​​from research to clinical use – that Arvid Carlsson himself advocated.

“We are honored that our research and clinical progress are recognized through the Arvid Carlsson Award. The award gives us further motivation to continue developing treatments that can change the lives of patients with severe, chronic diseases and in need of advanced therapy,” says Petter Björquist, CEO of Verigraft.